The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price is up 8% over the past year, to $20.44 per mL. One of its named manufacturing plants, Rechon Life Science AB, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.